We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA's ODS CHIEF DEFENDS INDEPENDENCE, WELCOMES SUGGESTED FIXES
The head of the FDA’s embattled Office of Drug Safety (ODS) acknowledged there are gaps in the agency’s postmarketing surveillance system for prescription drugs, but he vigorously defended the office’s record in monitoring marketed products and denied that the FDA drug safety group is under anybody’s thumb.